The US Federal Trade Commission suggests that Jazz Pharmaceuticals plc improperly listed its patent on a system for distributing Xyrem (sodium oxybate) in the US Food and Drug Administration’s “Orange Book” because the patent does not claim the drug itself or a method of using it.
The FTC filed an amicus brief in Jazz’s infringement suit against Avadel Pharmaceuticals plc in the US District Court...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?